Apheresis– tag –
-
Typewriter Therapeutics Secures $56M Series A for In Vivo CAR-T, Aiming to Streamline Cell Therapy Manufacturing
BioBucks USA Overview Typewriter Therapeutics has raised $56 million in Series A funding to advance its innovative in vivo CAR-T cell therapy, designed to reprogram T cells directly within the patient's body. This approach eliminates the... -
CAR-T Cell Therapy Established for Specific B-Cell Lymphomas/Leukemias, but Product Differentiation and Individualized Adaptation Crucial
Regenex Asia Singapore Overview CAR-T cell therapy is firmly established for specific B-cell lymphomas and leukemias, but its clinical utility hinges on aligning individual products with appropriate disease settings due to varying target... -
Kite and BBG Advanced Therapies Launch Mobile Leukapheresis Center in Texas to Enhance CAR T-Cell Therapy Patient Access and Streamline Supply Chain
Cellgenetherapyreview.com USA Overview Kite and BBG Advanced Therapies announced on July 9, 2026, the launch of a mobile leukapheresis center in Texas. This innovative initiative aims to significantly improve access to the apheresis proc...
1